Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VYC-12, marketed under the brand name Juvéderm Volite, is an injectable dermal filler developed by Allergan (now part of AbbVie) using the proprietary Vycross technology platform. It consists of a crosslinked hyaluronic acid (HA) gel that combines low and high molecular weight HA to achieve a high degree of crosslinking and cohesivity. Unlike traditional fillers designed for deep tissue volumization, VYC-12 is specifically intended for intradermal injection to improve skin quality by addressing superficial fine lines and enhancing hydration and elasticity. It acts within the extracellular matrix to bind water and provide structural support, with clinical effects lasting up to nine months for hydration and six months for skin smoothness.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on VYC-12.